Keytruda + chemo improved PFS as first-line therapy for advanced or recurrent endometrial carcinoma, regardless of MMR status

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a phase III NRG‑GY018 trial investigating Keytruda (pembrolizumab) in combination with standard of care chemotherapy (carboplatin and paclitaxel) for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient, the Keytruda regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients, regardless of mismatch repair status. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. 
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login